March 2016—Both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) halted ongoing first-line trials of idelalisib in combination with other agents due to an increased risk of serious adverse events including death, mostly due to infections.
This CME-certified prIME Rounds in chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL) Webcast focuses on recent advances in therapy and management of patients with these diseases.
Ian W. Flinn, MD, PhDSarah Cannon Research Institute
Nashville, Tennessee, United States
Ajay Gopal, MDUniversity of Washington and
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
This educational activity is designed for hematologists, oncologists, and other healthcare professionals involved in the management of patients with CLL and iNHL.
After successful completion of this educational activity, participants should be able to:
- Discuss recent clinical trial data regarding the safety and efficacy of novel treatment options for CLL and iNHL
- Employ best practices for treatment selection and integration of novel agents in patients with CLL and iNHL
- Discuss strategies to identify and manage treatment-related adverse events to improve quality of life and outcomes in patients with CLL and NHL
- Identify appropriate clinical trials in which to enroll patients with CLL and indolent NHL
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is provided by prIME Oncology.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is supported by grant from Gilead Sciences, Inc.
November 9, 2015
November 9, 2016